Clinical and Biochemical Outcomes in Transgender Individuals Undergoing Hormone Therapy: Protocol for a Systematic Review (Preprint)

Emily Sattora, Karen Teelin, Christopher Prendergast, Abigail Smith, James A. Evans, Aamer Imdad2024 · DOI

Gender-affirming hormone therapy (GAHT), typically involving exogenous testosterone or estrogen, is a cornerstone of care for many transgender and gender-diverse individuals. While clinical guidelines from organizations like the Endocrine Society and the World Professional Association for Transgender Health (WPATH) recommend regular monitoring of health markers such as lipid levels, the evidence supporting the specific frequency and necessity of this monitoring is often inconsistent or sparse. This protocol outlines a rigorous systematic review and meta-analysis designed to synthesize existing literature and provide a high-certainty evidence base for clinical monitoring in both adolescents and adults.

Addressing the Evidence Gap

Existing research indicates that GAHT can significantly alter body composition and lipid profiles. However, many previous reviews have lacked the methodological rigor required to account for the "risk of bias" or have excluded critical comparison groups, such as age-matched cisgender individuals. There is a significant need for a comprehensive synthesis of data that evaluates the magnitude of these physiological changes across different age groups and administration routes to inform safer, more effective long-term care. This study aims to address these gaps by applying the GRADE framework to existing observational data.

Study Objectives and Methodology

The primary objective of this study is to synthesize evidence from existing literature on the effect of exogenous hormone therapy on clinical and biochemical outcomes for transgender individuals. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, the research team will implement a multi-stage methodology:

  • Comprehensive Search Strategy: The authors will search several major medical databases, including PubMed, Scopus, EMBASE, Web of Science, the Cochrane Central Register for Controlled Trials, the WHO Global Index Medicus, and CINAHL.
  • Rigorous Study Selection: A three-stage screening process—comprising title/abstract screening, full-text review, and data extraction—will be conducted by two independent reviewers using Covidence software to ensure objectivity and accuracy.
  • Comparison Framework: The study will include prospective and retrospective observational cohort studies with at least one year of hormone exposure. Outcomes will be compared against baseline (pre-therapy) data and age-matched cisgender populations.
  • Statistical Analysis: Meta-analyses will utilize random-effect models. Furthermore, meta-regressions will be employed to investigate "effect modifiers"—variables such as age, duration of therapy, and route of administration (e.g., oral vs. transdermal vs. injectable) that might influence the results.

Holistic Outcome Mapping and Quality Control

The review tracks a wide array of metabolic and clinical markers to provide a complete picture of health. Primary outcomes include changes in or the development of abnormal lipid parameters. Secondary outcomes encompass BMI, weight, height, blood pressure, serum testosterone or estrogen levels, and the development of diseases such as hypertension, type-2 diabetes, fatty liver disease, and adverse cardiac events, as well as all-cause mortality.

To ensure the reliability of the findings, the team will use the ROBINS-I tool to assess the risk of bias in non-randomized studies, looking specifically for confounding variables or missing data common in transgender health research. Furthermore, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach will be used to determine the overall certainty of the evidence for each finding.

Future Implications and Subgroup Focus

By performing subgroup analyses for those under and over 19 years of age, the study addresses the specific physiological concerns of transgender youth, a population often underrepresented in long-term metabolic studies. The protocol also explicitly plans to evaluate whether the route of hormone delivery influences biochemical outcomes, which could lead to more personalized prescription practices.

While quantitative results are expected to be published in Spring 2025, the final review will serve as a critical foundation for future clinical guidelines and help researchers identify "knowledge gaps" where new primary studies are most urgently needed.

Summary updated

Abstract

<sec> <title>BACKGROUND</title> Monitoring of various clinical outcomes and parameters, such as lipid levels, is recommended in transgender individuals undergoing hormone therapies. However, comprehensive data to inform these recommendations is scarce. </sec> <sec> <title>OBJECTIVE</title> This study aims to conduct a systematic review and meta-analysis to synthesize evidence from existing literature on the effect of exogenous hormone therapy on clinical and biochemical outcomes for transgender adolescents and adults. </sec> <sec> <title>METHODS</title> We will search multiple electronic databases and will include prospective and retrospective observational studies with and without a control group. The study population will include transgender individuals undergoing hormone therapy with testosterone or estrogen. Comparisons will include age-matched, cisgender individuals and changes from baseline. Primary outcomes include changes in or the development of abnormal lipid parameters. Secondary outcomes include BMI, weight, height, and blood pressure for age, serum testosterone or estrogen levels, and development of disease including hypertension, diabetes, fatty liver disease, obesity, adverse cardiac events, as well as all-cause mortality. The meta-analysis will pool the studies where applicable, and meta-regressions will be conducted to evaluate effect modifiers. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach will be used to evaluate the overall certainty of evidence. </sec> <sec> <title>RESULTS</title> We will summarize the selection of the eligible studies using a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart. The results will be presented in a table summarizing the evidence. Data collection is ongoing, and the paper is expected to be published in Spring 2025. </sec> <sec> <title>CONCLUSIONS</title> This systematic review will summarize and evaluate the evidence of the clinical and biochemical outcomes associated with hormone therapies for transgender individuals. </sec> <sec> <title>CLINICALTRIAL</title> PROSPERO CRD42024483138; https://tinyurl.com/yc4sfvnb </sec> <sec> <title>INTERNATIONAL REGISTERED REPORT</title> PRR1-10.2196/57931 </sec>
BibTeX
@misc{sattora2024clinical,
  author = {Emily Sattora and Karen Teelin and Christopher Prendergast and Abigail Smith and James A. Evans and Aamer Imdad},
  title = {{Clinical and Biochemical Outcomes in Transgender Individuals Undergoing Hormone Therapy: Protocol for a Systematic Review (Preprint)}},
  year = {2024},
  doi = {10.2196/preprints.57931},
}
Figure